Citations

Clear

431 citation(s) found for "Schmidt, B".

Understanding Patients’ Current Acceptability of Artificial Intelligence During Colonoscopy for Polyp Detection: A Single Center Study
Schmidt, K., Barry, Brenda J. , Schmidt, K., Sood, S., Dilmaghani, Saam , Goyal, M., Barry, B., Zhu, Xin , Coelho–Prabhu, Nayantara

Mayo Clinic

Endoscopy | April 23, 2024 | Volume: 56 | Issue: S 02 | Pages: S175-S176

10.1055/s-0044-1783083 Get It

1151 Pharmacological Treatment of Pediatric Insomnia--A Successful Trial of Doxepin
Tu, Xinhang , Matarese, Christine, Lloyd, Robin M. , Sorensen, Channing, Schmidt, Scott, Baughn, Julie , Schmidt, Scott

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A493-A493

10.1093/sleep/zsae067.01151 Get It

Abstract Introduction Insomnia is a common sleep disorder in pediatric patients with neurodevelopmental disabilities. There are no FDA approved medications for insomnia in the pediatric population, and treatment can be challenging. We present a case of successful treatment of sleep maintenance insomnia in a 15-year-old male with doxepin with supportive actigraphy data. Report of case(s) A 15-year-old male with a past history pertinent for a genetic neurodevelopmental disorder, autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) was evaluated in Pediatric Sleep Medicine Clinic for long standing difficulties with sleep maintenance. He experienced frequent, prolonged nocturnal awakenings and early morning awakenings. Previous polysomnogram was negative for sleep disordered breathing. He previously trialed clonidine, guanfacine, trazodone, melatonin, and mirtazapine without significant benefit. Baseline actigraphy demonstrated frequent and prolonged nocturnal awakenings and early morning awakenings. He was initiated on doxepin 3 mg at bedtime, and it was subsequently increased to 6 mg at bedtime. Parental report and repeat actigraphy 4 months later (on doxepin 6 mg) demonstrated improvement in nocturnal awakenings and early morning awakenings. Conclusion Up to now, there are no FDA approved medications for the treatment of insomnia in the pediatric population. A prior study of patients with ASD and ADHD demonstrated the use of doxepin provided clinical improvement in sleep onset and maintenance insomnia based on subjective evidence with parental report. In this case, doxepin improved subjective report of insomnia and correlated with objective findings on actigraphy. Support (if any) NA
TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Minnie, Simone A. , Waltner, Olivia G. , Zhang, Ping , Takahashi, Shuichiro , Nemychenkov, Nicole S, Ensbey, Kathleen S., Schmidt, Christine R. , Legg, Samuel R.W., Comstock, Melissa , Boiko, Julie R. , Nelson, Ethan , Bhise, Shruti S. , Wilkens, Alec B. , Koyama, Motoko , Dhodapkar, Madhav V. , Chesi, Marta , Riddell, Stanley R. , Spencer, Andrew , Green, Damian J , Spencer, Andrew , Furlan, Scott N , Hill, Geoffrey R , Koyama, Motoko , Hill, Geoffrey R.

Mayo Clinic

Science Immunology | April 19, 2024 | Volume: 9 | Issue: 94 | Pages: No page available

10.1126/sciimmunol.adg1094 | PMID 38640253 Get It

Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

No container title available | April 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.2 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Rehabilitation Treatment Specification System: Content and Criterion Validity Across Evidence-Based Voice Therapies for Muscle Tension Dysphonia
Stan, Jarrad H. Van , Roy, Nelson , Stemple, Joseph C., Gartner-Schmidt, Jaqueline, Gillespie, Amanda I. , Duffy, Joseph R. , Turkstra, Lyn S. , Van Stan, Jarrad H , Duffy, Joseph R , Turkstra, Lyn , Roy, Nelson , Whyte, John

Mayo Clinic

American Journal of Speech-Language Pathology | April 10, 2024 | Volume: 33 | Issue: 4 | Pages: 1774-1791

10.1044/2024_ajslp-23-00362 | PMID 38597797 Get It

Purpose: Systematically improving voice therapy outcomes is challenging as the clinician actions (i.e., active ingredients) responsible for improved patient functioning (i.e., targets) are relatively unknown. The theory-driven Rehabilitation Treatment Specification System (RTSS) and standard, voice-specific terminology based on the RTSS (RTSS-Voice) may help address this problem. This qualitative study evaluated if the RTSS and RTSS-Voice can describe four evidence-based voice therapies for muscle tension dysphonia without missing critical aspects (content validity) and identify commonalities and differences across them (criterion validity). Method: Qualitative interviews were completed between the clinicians (protocol experts) who developed and/or popularized the vocal function exercises, laryngeal reposturing, circumlaryngeal massage, and conversation training therapies as well as RTSS experts to produce RTSS specifications that met two consensus criteria: (a) The protocol expert agreed that the specification represented their treatment theory, and (b) the RTSS experts agreed that the specifications correctly adhered to both the RTSS framework and the RTSS-Voice's standard terminology. Results: The RTSS and RTSS-Voice comprehensively described voice therapy variations across and within the four diverse treatment programs, needing only the addition of one new target: overall auditory-perceptual severity. Conclusions: The RTSS and RTSS-Voice exhibited strong content validity. The standard RTSS-Voice terminology helped identify, for the first time, commonalities and differences in treatment ingredients, targets, and mechanisms of action across four treatments developed for the same patient population. In the long term, the RTSS and RTSS-Voice could provide the framework for an ever-growing collection of clinically meaningful and evidence-based therapy algorithms with potential to improve research, education, and clinical care. Supplemental Material: https://doi.org/10.23641/asha.25537624
Social Determinants of Health and Redirection of Care for Infants Born Extremely Preterm
Bann, Carla , Vohr, Betty R. , McGowan, Elisabeth C. , Harmon, Heidi M. , Hintz, Susan R. , Duncan, Andrea F. , Polin, Richard A. , Laptook, Abbot R. , Mayne, Julie, Lamberson, Vita, Keszler, Mary Lenore, Hensman, Angelita M. , Vieira, Elisa , Pierre, Lucille St., Burke, Robert T., Alksninis, Barbara, Leach, Teresa M., Knoll, Andrea M., Moffat, Stephanie, Newman, Nancy S., Wilson-Costello, Deanne E. , Siner, Bonnie S., Friedman, Harriet, Truog, William E., Pallotto, Eugenia K. , Kilbride, Howard W. , Gauldin, Cheri, Holmes, Anne, Johnson, Kathy, Scott, Allison, Parimi, Prabhu S., Gaetano, Lisa, Merhar, Stephanie L. , Schibler, Kurt, Poindexter, Brenda B. , Cahill, Tanya E., Dudley, Juanita , Gratton, Teresa L., Grisby, Cathy, Henkes, Lisa, Kirker, Kristin, Stacey, Sara, Wuertz, Sandra, Cotten, C. Michael , Goldberg, Ronald N., Goldstein, Ricki F., Malcolm, William , Ashley, Patricia L., Mago-Shah, Deesha, Finkle, Joanne, Fisher, Kimberley A. , Gustafson, Kathryn E. , Bose, Carl , Bernhardt, Janice, Bose, Gennie, Clark, Cindy, Wereszczak, Janice, Warner, Diane, Talbert, Jennifer, Kicklighter, Stephen D. , Bentley, Alexandra, Edwards, Laura , Rhodes-Ryan, Ginger, Carlton, David P., Loggins, Yvonne, Adams‐Chapman, Ira , Bottcher, Diane I., Carter, Sheena L., Hale, Ellen C., Kendrick-Allwood, Salathiel, Laursen, Judith, LaRossa, Maureen Mulligan, Mackie, Colleen, Sanders, Amy , Smikle, Gloria V., Wineski, Lynn, Walsh, Michele C. , Bremer, Andrew A. , Higgins, Rosemary D. , Archer, Stephanie Wilson , Sokol, Gregory M. , Papile, L.A., Herron, Dianne E., Hines, Abbey C. , Lytle, Carolyn, Smiley, Lucy, Wilson, Leslie Dawn, Watkins, Donna, Gunn, Susan, Joyce, Jeff, Tyson, Jon E., Kennedy, Kathleen A. , Mosquera, Ricardo A. , Eason, Elizabeth, Stephens, Emily K. , Alaniz, Nora I., Allain, Elizabeth, Arldt-McAlister, Julie, Boricha, Fatima, Burson, Katrina, Garcia, Carmen, Hall, Donna J., John, Janice , Jones, Patrick M., Lillie, M. Layne, Mason, Carrie M., Martin, Karen , Martin, Sara C., McDavid, Georgia E., McKee, Shannon L. , Poe, Michelle, Rennie, Kimberly , Reddy, Tina, Rodgers, Shawna, Siddiki, Saba Khan, Sperry, Daniel K., Tate, Patti L. Pierce, Wright, Sharon L., Zanger, Dinorah, Jadcherla, Sudarshan R. , Timan, Christopher J., Luzader, Patricia, Batterson, Nancy, Baugher, Hallie, Beckford, Demi R., Burkhardt, Stephanie, Carey, Helen , Chao, Michelle, Cira, Courtney, Clark, Erna, DeSantis, Brittany, Fowler, Aubrey, Gutentag, Julie, Grothause, Jennifer L., Hague, Cole , Levengood, Katelyn, Marzec, Laura, McCool, Jacqueline, Miller, Bethany, Nelin, Mary Ann , Park, Courtney, Purnell, Jessica, Seabrook, Ruth , Shadd, Julie C., Small, Kristi , Stein, Melanie, Sullivan, Margaret, Sullivan, Rox Ann, Warnimont, Kyrstin, Yossef‐Salameh, Lina, Fearns, Erin, Wallace, Dennis, Auman, Jeanette O’Donnell , Gabrio, Jenna, Huitema, Carolyn M. Petrie , Zaterka-Baxter, Kristin M. , Meurs, Krisa P. Van , Chock, Valerie Y. , Stevenson, David K. , Ball, M. Bethany , Bahmani, Dona, Adams, Marian M. , Bentley, Barbara, DeAnda, Maria Elena, DeBattista, Anne M., Earhart, Beth, Huffman, Lynne C. , Krueger, Casey E., Lucash, Ryan E., Proud, Melinda S., Reichert, Elizabeth N., Weiss, Hali E., Williams, R. Jordan , Peralta-Carcelén, Myriam , Collins, Monica V., Cosby, Shirley S., Bailey, Kirstin J., Biasini, Fred J., Chopko, Stephanie A., Domnanovich, Kristy A., Jno-Finn, Chantel J., Ladinsky, Morissa, Moses, Mary Beth, Buie, Cindie, McNair, Tara E., Phillips, Vivien A., Preskitt, Julie , Rector, Richard V., Stringer, Kimberlly, Whitley, Sally, Chapman, Sheree York, Devaskar, Uday, Garg, Meena, Purdy, Isabell B., Chanlaw, Teresa , Geller, Rachel , Johnson, Karen, Eastman, Diane L., Walker, Jacky R., Goeke, Claire A., Schmelzel, Mendi L., Faruqui, Sarah E., Coulter, Brenda J., Schrimper, Bailey M., Jellison, Sydney S., Knosp, L.K., Arnold, Sandra J., Andrews, Haley A., Ellsbury, Dan L., Bass, Donia B., Tud, Tracy L., Baack, Michelle , Richards, Laurie A., Henning, Megan M., Elenkiwich, Chelsey, Broadbent, Megan, Muyden, Sarah Van, Brodkorb, Aimee, Watterberg, Kristi L. , Fuller, Janell, Ohls, Robin K. , Lacy, Conra Backstrom, Hartenberger, Carol, Beauman, Sandra Sundquist , Hanson, Mary, Lowe, Jean, Kuan, Elizabeth, Eichenwald, Eric C. , Abbasi, Soraya, Chaudhary, Aasma S. , Cucinotta, Dara M., Bernbaum, Judy, Gerdes, Marsha , Ghavam, Savin, Hurt, Hallam, Snyder, Jonathan, Ziolkowski, Kristina, Dhawan, Megan , Booth, Lauren, Catts, Christine, D’Angio, Carl T., Guillet, Ronnie , Myers, Gary J. , Reynolds, Anne Marie , Wadkins, Holly I.M., Sacilowski, Michael G., Jensen, Rosemary L., Merzbach, Joan, Zorn, William, Farooq, Osman , Maffett, Dee, Williams, Ashley, Hunn, Julianne, Guilford, Stephanie , Yost, Kelley, Rowan, Mary, Prinzing, Diane, Bowman, Melissa, Reubens, Linda J., Scorsone, Ann Marie, Harley-McAndrew, Michelle, Fallone, Caitlin, Binion, Kyle, Orme, Constance, Sabaratnam, Premini , Jones, Rachel , Boylin, Elizabeth, Rochez, Daisy, Li, Emily, Kachelmeyer, Jennifer , McKee, Kimberly G., Coleman, Kelly R., Moreland, Melissa, Cavanaugh, Brenna, Wyckoff, Myra H. , Heyne, Roy J. , Vasil, Diana M., Adams, Sally S., Chen, Lijun , Leon, Maria Magdalena, Duran, Joanne, Eubanks, Frances, McDougald, Rebecca, Pavageau, Lara, Sepulveda, Pollieanna , Guzman, Alicia, Harrod, M. J. E., Heyne, Elizabeth T., Madden, Linda A., Lee, Lizette E. , Puentez, Anna E., Tolentino-Plata, Kristine , Boatman, Cathy Twell, Vera, Azucena, Waterbury, Jillian, Yoder, Bradley A. , Baserga, Mariana , Faix, Roger G., Minton, Stephen D., Sheffield, Mark J., Rau, Carrie A., Baker, Shawna, Burnett, Jill, Christensen, Susan, Bledsoe, Laura Cole, Cunningham, Sean D. , Davis, Brandy, Elmont, Jennifer O., Hall, Becky, Jensen, Erika R., Loertscher, Manndi C., Marchant, Trisha, Maxson, Earl, McGrath, Kandace M., Mickelsen, Hena G., Morshedzadeh, Galina, Parry, Dilys M. , Reich, Brixen A., Schaefer, Susan T., Stout, Kelly, Stuart, Ashley L., Weaver-Lewis, Kimberlee, Winter, Sarah , Woodbury, Kathryn D., Osborne, Karen A., Bird, Karie, Coleman, Kathleen, Francom, Barbara L., Jordan, Jamie, Steffen, Mike, Tice, Katherine, Shankaran, Seetha , Natarajan, Girija , Pappas, Athina, Sood, Beena G. , Bajaj, Monika , February, Melissa, Agarwal, Prashant , Chawla, Sanjay , Bara, Rebecca, Childs, Kirsten, Woldt, Eunice, Goldston, Laura A., Wiggins, Stephanie A., Christensen, Mary, Carlson, Martha, White, Diane F., Baack, Michelle L , Brumbaugh, Jane E. , Bell, Edward F. , Travers, Colm P. , Carlo, Waldemar A. , Keszler, Martin , Watson, Victoria E. , Hibbs, Anna Maria , Kim, Jae Hong , Yolton, Kimberly , Russell, David G. , Laughon, Matthew Maxwell , White, Donna, Patel, Ravi M. , Stoll, Barbara J. , Sewell, Elizabeth , Maitre, Nathalie L. , (deceased), Jeff Joyce, Khan, Amir M , Rysavy, Matthew A. , Dempsey, Allison G. , White, Michelle, Sánchez, Pablo J. , Slaughter, Jonathan L. , Nelin, Leif Daniel , Yeates, Keith Owen , Fortney, Christine A. , Keim, Sarah A. , Newton, Julia L. , Pietruszewski, Lindsay , Das, Abhik , Gantz, Marie G. , Wiener, Laura Elizabeth , Crawford, Margaret M. , Newman, Jamie E. , Parlberg, Lindsay M. , Taylor, Heather Lee , Ambalavanan, Namasivayam , Colaizy, Tarah T. , Widness, John A. , DeMauro, Sara B. , Schmidt, Barbara Kristina , Kirpalani, Haresh Murli , Mancini, Toni, Lakshminrusimha, Satyan , Kent, Alison , Brion, Luc P. , Leon, Maria M. De, Harrod, Michelle, Parry, D. Melody, Coleman, Kathleen, Barks, John

Mayo Clinic

JAMA Pediatrics | March 11, 2024 | Volume: 178 | Issue: 5 | Pages: 454

10.1001/jamapediatrics.2024.0125 | PMID 38466268 Get It

ImportanceRedirection of care refers to withdrawal, withholding, or limiting escalation of treatment. Whether maternal social determinants of health are associated with redirection of care discussions merits understanding.ObjectiveTo examine associations between maternal social determinants of health and redirection of care discussions for infants born extremely preterm.Design, Setting, and ParticipantsThis is a retrospective analysis of a prospective cohort of infants born at less than 29 weeks’ gestation between April 2011 and December 2020 at 19 National Institute of Child Health and Human Development Neonatal Research Network centers in the US. Follow-up occurred between January 2013 and October 2023. Included infants received active treatment at birth and had mothers who identified as Black or White. Race was limited to Black and White based on service disparities between these groups and limited sample size for other races. Maternal social determinant of health exposures were education level (high school nongraduate or graduate), insurance type (public/none or private), race (Black or White), and ethnicity (Hispanic or non-Hispanic).Main Outcomes and MeasuresThe primary outcome was documented discussion about redirection of infant care. Secondary outcomes included subsequent redirection of care occurrence and, for those born at less than 27 weeks’ gestation, death and neurodevelopmental impairment at 22 to 26 months’ corrected age.ResultsOf the 15 629 infants (mean [SD] gestational age, 26 [2] weeks; 7961 [51%] male) from 13 643 mothers, 2324 (15%) had documented redirection of care discussions. In unadjusted comparisons, there was no significant difference in the percentage of infants with redirection of care discussions by race (Black, 1004/6793 [15%]; White, 1320/8836 [15%]) or ethnicity (Hispanic, 291/2105 [14%]; non-Hispanic, 2020/13 408 [15%]). However, after controlling for maternal and neonatal factors, infants whose mothers identified as Black or as Hispanic were less likely to have documented redirection of care discussions than infants whose mothers identified as White (Black vs White adjusted odds ratio [aOR], 0.84; 95% CI, 0.75-0.96) or as non-Hispanic (Hispanic vs non-Hispanic aOR, 0.72; 95% CI, 0.60-0.87). Redirection of care discussion occurrence did not differ by maternal education level or insurance type.Conclusions and RelevanceFor infants born extremely preterm, redirection of care discussions occurred less often for Black and Hispanic infants than for White and non-Hispanic infants. It is important to explore the possible reasons underlying these differences.
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America
Hassan, Manal M. , Li, Donghui , Han, Younghun , Choi, Jiyeon , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Ghobrial, R. Mark , Santella, Regina M. , Nguyen, Mindie H. , Liu, Geoffrey , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem B. , Chang, Ping , Li, Yanan , Chun, Yun Shin , Lee, Sunyoung S. , Gu, Jian , Hawk, Ernest T. , Huff, Chad , Rashid, Asif , Amin, Hesham M. , Beretta, Laura , Wolff, Robert A. , Antwi, Samuel O. , Patt, Yehuda Z., Hwang, Lu‐Yu, Schmidt, Mikayla A. , White, Donna L. , Goss, John A. , Khaderi, Saira, Marrero, Jorge A. , Cigarroa, Francisco , Roberts, Lewis R. , Han, Younghun , Roberts, Lewis R , Antwi, Samuel O , Liu, Geoffrey , Parikh, Neehar D , Beretta, Laura , Gu, Jian , Byun, Jinyoung , Hatia, Rikita , Long, Erping , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Yuan, Jian-Min , Singal, Amit G. , Jalal, Prasun K. , Kono, Yuko , Shah, Dimpy P. , Nguyen, Mindie H. , Kim, Richard D. , Li, Yanan, Sun, Ryan , Klein, Alison P. , Zhang, Karen , Shah, Pankil , Kaseb, Ahmed O , Amos, Christopher I.

Mayo Clinic

Hepatology | February 21, 2024 | Volume: 80 | Issue: 1 | Pages: 87-101

10.1097/hep.0000000000000800 | PMID 38381705 Get It

Background and Aims: Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been studied systematically by genome-wide approaches in large numbers of individuals from European descent populations (EDP). Approach and Results: We conducted a 2-stage genome-wide association study (GWAS) on HCC not affected by HBV infections. A total of 1872 HCC cases and 2907 controls were included in the discovery stage, and 1200 HCC cases and 1832 controls in the validation. We analyzed the discovery and validation samples separately and then conducted a meta-analysis. All analyses were conducted in the presence and absence of HCV. The liability-scale heritability was 24.4% for overall HCC. Five regions with significant ORs (95% CI) were identified for nonviral HCC: 3p22.1, MOBP, rs9842969, (0.51, [0.40–0.65]); 5p15.33, TERT, rs2242652, (0.70, (0.62–0.79]); 19q13.11, TM6SF2, rs58542926, (1.49, [1.29–1.72]); 19p13.11 MAU2, rs58489806, (1.53, (1.33–1.75]); and 22q13.31, PNPLA3, rs738409, (1.66, [1.51–1.83]). One region was identified for HCV-induced HCC: 6p21.31, human leukocyte antigen DQ beta 1, rs9275224, (0.79, [0.74–0.84]). A combination of homozygous variants of PNPLA3 and TERT showing a 6.5-fold higher risk for nonviral-related HCC compared to individuals lacking these genotypes. This observation suggests that gene-gene interactions may identify individuals at elevated risk for developing HCC. Conclusions: Our GWAS highlights novel genetic susceptibility of nonviral HCC among European descent populations from North America with substantial heritability. Selected genetic influences were observed for HCV-positive HCC. Our findings indicate the importance of genetic susceptibility to HCC development.
Artificial Intelligence–Enabled Stool Analysis for Lactulose Titration Assistance in Hepatic Encephalopathy Through a Smartphone Application
Chara, Beatriz Sordi , Hara, Kamalpreet S. , Schmidt, Kathryn A. , Kassmeyer, Blake A., Anstey, Jacob, Tiede, David, Kamath, Patrick S. , Shah, Vijay H. , Bajaj, Jasmohan S. , Kraus, Asaf, Sordi Chara, Beatriz , Penrice, Daniel , Kamath, Patrick S , Bajaj, Jasmohan S , Penrice, Daniel D. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | January 19, 2024 | Volume: 119 | Issue: 5 | Pages: 982-986

10.14309/ajg.0000000000002656 | PMID 38240303 Get It

INTRODUCTION: Management of hepatic encephalopathy relies on self-titration of lactulose. In this feasibility trial, we assess an artificial intelligence–enabled tool to guide lactulose use through a smartphone application. METHODS: Subjects with hepatic encephalopathy on lactulose captured bowel movement pictures during lead-in and intervention phases. During the intervention phase, daily feedback on lactulose titration was delivered through the application. Goals were determined according to number of bowel movement and Bristol Stool Scale reports. RESULTS: Subjects completed the study with more than 80% satisfaction. In the lead-in phase, less compliant subjects achieved Bristol Stool Scale goal on 62/111 (56%) of days compared with 107/136 (79%) in the intervention phase ( P = 0.041), while the most compliant subjects showed no difference. Severe/recurrent hepatic encephalopathy group achieved Bristol Stool Scale goal on 80/104 (77%) days in the lead-in phase and 90/110 (82%) days in the intervention phase ( P = NS), compared with 89/143 (62%) days and 86/127 (68%) days in the stable group. DISCUSSION: Dieta application is a promising tool for objective Bowel Movement/Bristol Stool Scale tracking for hepatic encephalopathy and may potentially be used to assist with lactulose titration.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Zhang, Ting , Bouchonville, Kelly J. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

No container title available | January 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.1 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Temesgen, Zoey B , Stroka, Deborah , Largiadèr, Carlo R , Offer, Steven M , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

eLife | January 10, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.94075 | PMID 38686795 Get It

Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.